Phase 1 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily, have been fully informed about the study, and have signed a consent form
• People aged 18 to 79 years
• People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed through laboratory tissue testing
• People who have had surgery where the entire visible tumour was removed (either with clear margins or close margins)
• People whose cancer, based on post-surgery pathology results, has not spread to distant parts of the body and falls within certain stage categories (confirm with trial site)
• People whose tumour tissue tests positive for a protein called CLDN18.2, detected through a special staining test
• People who have recovered from surgery and have completed 3 months of standard follow-up cancer treatment
• People who have an abnormal level of a blood marker called CA19-9
• People who have suitable veins to allow a blood cell collection procedure called leukapheresis
• People who are in good general health, able to carry out normal daily activities with little or no limitation (based on a standard medical scoring system)
• People who have adequate liver, kidney, and other organ function
• People of childbearing potential who are willing to use effective contraception throughout the study

Who may not be able to join:

• People who received treatment for pancreatic cancer before their surgery (neoadjuvant therapy)
• People whose pancreatic cancer was classified as "borderline resectable" (meaning it was on the boundary of being surgically removable)
• People who have had, or currently have, pancreatic cancer that has spread or come back locally
• People who show signs of fluid build-up in the abdomen caused by cancer (malignant ascites)
• People who have conditions that could affect CA19-9 blood marker levels, such as bile duct inflammation, pancreatitis, or blocked bile flow (jaundice)
• People who still have significant side effects from previous treatments that have not sufficiently resolved, with some exceptions as assessed by the trial doctor
• People who are pregnant or breastfeeding
• People who test positive for HIV, syphilis (Treponema pallidum), or Hepatitis C (HCV)
• People who have any active infections, including tuberculosis, Hepatitis B, Epstein-Barr virus, CMV, or COVID-19
• People who have significant thyroid problems
• People with a known allergy to immunotherapy drugs or to the ingredients of the study treatment (CT041), or who have a history of serious allergic reactions
• People who are considered at high risk of bleeding or a hole forming in the digestive tract
• People who have an active autoimmune disease (such as psoriasis or rheumatoid arthritis) or conditions that require long-term immune-suppressing medication
• People who have previously had an organ transplant or are waiting for one
• People who need anticoagulant (blood-thinning) medication
• People who are currently taking or expected to need long-term antiplatelet therapy (medication that reduces blood clotting) during the study
• People who have had major surgery or a serious injury within 4 weeks before the blood cell collection procedure, or who are expected to have major surgery during the study
• People who have previously received any gene-modified cell therapies, such as CAR-T or TCR-T treatments
• People who have other serious medical conditions that the trial doctors consider would prevent safe participation
• People whose blood oxygen levels are at or below 95%
• People who show signs of nervous system disease or significant abnormalities on neurological examination
• People who have had another type of cancer within the past 3 years or currently, with some exceptions for very low-risk cancers such as certain skin or cervical cancers (confirm with trial site)
• People who have received a live attenuated vaccine within 4 weeks before the blood cell collection procedure, or who plan to receive one during the study
• People who are unable or unwilling to follow the study requirements as assessed by the trial doctors

Important: Always verify eligibility with the trial site directly before applying.